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States Seek to Boost Price 
Transparency at Retail 
Pharmacy Level
As the rising costs of prescription drugs 
and increasing numbers of uninsured 
Americans have led policy makers to 
examine different approaches toward 
helping consumers better afford the 
medications they need, many state gov-
ernments are focusing on initiatives 
to increase price transparency in retail 
pharmacy markets. These states have 
implemented Web sites that publish prices 
charged by local pharmacies for common 
prescription medications to help consum-
ers identify and purchase from the phar-
macies offering the lowest prices. 
The current push to make retail phar-
macy prices accessible to consumers is 
part of a much broader movement to 
increase price transparency throughout 
the health care system. Efforts to encour-
age price-based shopping for hospital and 
physician services have encountered wide-
spread concerns, both on grounds that 
prices for complex services are difficult to 
measure and compare accurately and that 
quality varies substantially across provid-
ers. Experts agree, however, that prescrip-
tion drugs are much easier to shop for 
than other, more complex health services. 
First, for any given prescription, prices are 
completely comparable across providers. 
Second, quality variations across retail 
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2pharmacies do not appear to be a major 
concern to experts familiar with this mar-
ket. Pharmacies do differ significantly on 
some dimensions, such as location and 
customer service, but these are likely to be 
characteristics that consumers can assess 
themselves.
Some observers are concerned about 
one aspect of shopping for drugs: If a 
consumer needs multiple medications and 
buys each at a different pharmacy to maxi-
mize cost savings, no single pharmacy will 
be aware of the consumer’s full medication 
list, and the consumer will not be alerted 
to any adverse drug interactions that might 
occur.1 A leading consumer organization, 
however, notes that while such concerns 
are valid, they should not preclude mul-
tiple-pharmacy shopping by consumers, 
as long as consumers present their full 
medication list and ask about possible drug 
interactions at each pharmacy they use.2
While conditions in the retail phar-
macy market generally are conducive to 
consumer shopping, this market has some 
characteristics that may limit the useful-
ness or relevance of drug price comparison 
initiatives launched by state governments. 
First, programs that compare prices only 
at pharmacies located within a state do not 
take into account the presence of online 
pharmacies, both in the u.S. and abroad, 
that often sell drugs for substantially less 
than local pharmacies. 
Second, insured and uninsured con-
sumers face different retail prices for their 
prescriptions, and the usual and customary 
prices posted by state drug price compari-
son initiatives generally are relevant only to 
the uninsured.3 Insured consumers typical-
ly are eligible for prescription drug prices 
negotiated by pharmacy benefit managers 
(PbMs), which use volume purchasing 
power to obtain lower prices. Even insured 
consumers who are paying completely out 
of pocket—because they have not yet met a 
deductible—typically are eligible for these 
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Data Source
Interviews. HSC researchers conducted interviews with state policy makers, pharmacy industry 
experts, representatives of consumer advocacy organizations and other stakeholders and experts 
to discuss their views on pharmacy price transparency issues. In addition, for states with drug 
price comparison initiatives, HSC contacted state agency staff and private data contractors via 
e-mail and telephone to gather information about these programs. 
Top 10 list of commonly used drugs. A major health insurer provided HSC a list of the 10 drugs 
with the highest dollar amount expenditures (during the fourth quarter of 2006) for paid phar-
macy claims among that insurer’s commercial plans. A physician consultant reviewed the drug 
list to select a common dosage level and formulation for each drug. 
Consumer Profiles. The consumer profiles were developed by a physician consultant to represent 
different age groups, health conditions and combinations of generic and brand name drugs to 
capture a range of drug needs. The consumer profiles represent actual patients in the physician 
consultant’s practice.
MyFloridaRx.com. The Florida Web site, MyFloridaRx.com, is a joint initiative between the 
Office of the Attorney General, which publishes the price data, and the Agency for Health Care 
Administration (AHCA), the Medicaid administrator in Florida. On a monthly basis, AHCA 
calculates the average usual and customary prices for the 100 most commonly used brand-name 
drugs and their generic substitutes (totaling approximately 650 formulations) for the pharmacies 
that filled at least one Medicaid prescription for those drugs in that month. According to AHCA, 
the usual and customary price is comparable to the price paid by an uninsured customer, exclud-
ing any drug discounts. Price data were downloaded from MyFloridaRx.com May-July 2007; the 
prices posted on MyFloridaRx.com were reported by the Web site’s documentation as applying to 
pharmacy prices during April 2007.
Number of Pharmacies: AHCA staff provided HSC researchers with county-specific counts of 
the number of pharmacies submitting at least one Medicaid claim containing a usual and custom-
ary price during April 2007. These counts were used to calculate the total number of pharmacies 
in each of the urban, suburban and rural markets examined in this report. The total number of 
retail pharmacies in each market may be greater than these counts.
Price Accuracy: For drugs on the Top 10 list and consumer profiles that match the formulation 
on MyFloridarx.com, the prices reported in this study are exactly as they appear on the Web site. 
Definition and Selection of Markets. Price data were analyzed in three markets (urban, sub-
urban, rural) with varying concentrations of pharmacies to assess the extent to which consum-
ers can comparison shop. Each market was constructed using population and land area data 
(obtained from the u.S. Census bureau) in conjunction with population density and travel 
distance criteria based upon Medicare/TrICArE pharmacy access standards (u.S. Department 
of Health and Human Services, Office of Inspector General, “retail Pharmacy Participation in 
Medicare Part D Prescription Drug Plans in 2006”).
The urban market of Hialeah, Fla., (in Miami-Dade County) was purposively selected because •	
it contains a high number of pharmacies and meets a population density of at least 3,000 indi-
viduals per square mile and has a land area that is approximately equal to a travel distance of 
2.5 miles from the center of the market. This urban market contains 70 pharmacies.
The suburban market near Tallahassee (Leon County) was defined by selecting a zip code with •	
a population density of 1,000-3,000 people per square mile, then constructing a radius of 5 
miles from that zip code to approximate a reasonable travel distance for a suburban pharmacy 
consumer. The suburban market encompassed all or part of zip codes: 32301, 32303, 32304, 
32309 and 32312. This suburban market includes 29 pharmacies.
Putnam County was selected as the rural market in this analysis because it is a county with a •	
high proportion of the population living in a rural area. This county’s land area approximates a 
radius of about 15 miles from the center of the county, which is considered a reasonable travel 
distance for a rural pharmacy consumer. This rural market contains 11 pharmacies.
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negotiated prices and often have access 
to online price tools provided by PbMs. 
It would be more accurate, therefore, to 
regard the true audience for these state 
initiatives as the subgroup of uninsured 
people needing prescription drugs, rather 
than the larger population of all “consum-
ers” or all “state residents” that most state 
programs have identified as their audience.
In addition, the usefulness and relevance 
to consumers of states’ drug price com-
parison initiatives are largely determined 
by how well each state implements its pro-
gram—in particular, how comprehensive, 
accurate and current the price information 
is, and how easy the Web site is to access, 
navigate and understand. This study pres-
ents the findings of an assessment of state 
drug price comparison programs (see Data 
Source), identifies several key factors limit-
ing the programs’ usefulness to consumers, 
and presents key policy options for states 
seeking to help consumers reduce prescrip-
tion drug costs.
State Web Sites          
Share Key Limitations      
on Price Information
As of late 2007, 10 states were actively 
maintaining Web sites providing prescrip-
tion drug prices available at the state’s retail 
pharmacies (see Table 1). More states, 
including California, are about to launch 
Web sites, while a few states, including 
Ohio and Washington, have discontinued 
previous initiatives. The 10 active state Web 
sites vary considerably on a number of 
key dimensions: the number of drugs with 
prices reported, the number of formula-
tions reported per drug, the duration of the 
data reporting period, and the frequency of 
price data updates. 
Data Source and Data Comprehen-
siveness. Most states with drug price com-
parison Web sites determine which drugs 
to include by consulting lists of commonly 
prescribed drugs—either a state-specific 
list from the state Medicaid agency or a 
national list obtained from commercial 
sources. Among the state Web sites, the 
number of drugs with price information 
varied widely, ranging from as few as 26 
drugs in Maryland to as many as 400 
drugs in Minnesota. Two states, Missouri 
and New Hampshire, include any drug for 
which a Medicaid claim was submitted 
during the reporting period.4 Some states 
exclude drugs that have the potential to be 
abused—including painkillers like hydro-
codone and lifestyle drugs like Viagra—no 
matter how commonly prescribed.
Most state Web sites provide price data 
for multiple formulations of the same drug, 
which often can be prescribed in several 
dosage levels and forms (e.g., capsule, liq-
uid). Florida, for example, presents price 
data for 650 different drug formulations, 
representing 100 distinct drugs.5 In con-
trast, Maryland offers price data for only 
one formulation per drug—an approach 
that limits the Web site’s usefulness. 
Comprehensiveness of drug price infor-
mation depends not just on the number of 
drugs and formulations covered, but also 
the completeness of price information pro-
vided for those drugs. For example, a Web 
site that has a long drug list but contains 
a great deal of missing price information 
would offer consumers limited shop-
ping opportunities. The analysis found 
that, among all the states with drug price 
comparison Web sites, none has a data col-
lection approach that provides complete 
pharmacy price data, because none requires 
pharmacies to report drug prices.
All but one of the states with drug 
price comparison Web sites use Medicaid 
claims data to obtain price information. 
Specifically, usual and customary price data 
are collected from claim forms submitted 
by pharmacies for prescription drug trans-
actions for Medicaid patients. The usual 
and customary price is not the actual price 
paid by Medicaid for prescription drugs; it 
generally represents the retail price that a 
pharmacy charges to a cash-paying custom-
er, absent any discount. In many states, this 
price often is reported on Medicaid claim 
forms. using these prices obtained from 
Medicaid claims has been popular among 
states undertaking price transparency ini-
tiatives, largely because the data are read-
ily available to state governments, which 
incur little additional cost in making the 
information available on state-hosted Web 
sites. In addition, this data collection strat-
egy involves no added reporting burden or 
cost to retail pharmacies, and so does not 
encounter resistance from pharmacies or 
their trade associations. However, the clear 
drawback to using Medicaid claims data is 
that price information will only be available 
on the Web site in cases where a pharmacy 
submitted a Medicaid claim that contained 
usual and customary price information 
for a particular drug during the reporting 
period.
New york is the only state that does not 
rely on Medicaid claims data for prescrip-
tion drug retail price information.6  A 2002 
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Comprehensiveness of drug price information depends not just on the 
number of drugs and formulations covered, but also the completeness 
of price information provided for those drugs. 
state law requires that retail pharmacies 
provide walk-in customers with prescrip-
tion price lists on request. The New york 
drug price comparison program currently 
uses volunteers to collect these price lists 
from retail pharmacies. To date, this data 
collection approach has resulted in severe-
ly limited price information. A search 
of the New york Web site revealed, for 
example, that price data for the most com-
monly prescribed drugs, such as Lipitor, 
were available for only four pharmacies in 
Manhattan. In addition, the price infor-
mation was not very current: A Web site 
search conducted in October 2007 found 
price data pertaining to April 2007. 
Timeliness of Price Information. Most 
states with drug comparison Web sites 
have a one-month reporting period and 
a monthly data update schedule. This 
schedule, if adhered to, would allow con-
sumers to access relatively recent price 
data. An examination of state Web sites, 
however, found that some states’ data 
updates have lagged behind schedule by a 
few months, so that the posted price infor-
mation was not as current as intended. 
Center for Studying Health System Change Research Brief No. 1 • February 2008
4
Table 1 
States with Drug Price Comparison Web Sites (as of November 2007)
State (Launch Year) Web Site Address Price Data 
Source
Number of Drugs 
(Formulations) 
as Reported by 
the State1,2
Duration of 
Reporting 
Period
Frequency 
of Price 
Updates3
Connecticut (2005) www.ct.gov/ag/cwp/view.asp?a=2106 
&q=294076
Medicaid 
claims
32 (40) 1 month
Monthly
Florida (2005)
www.myfloridarx.com
Medicaid 
claims
100 (650) 1 month Monthly
Maryland (2004)
www.oag.state.md.us/drugprices
Medicaid 
claims
26 (26) 2 months4 Monthly
Michigan (2006)
www.michigandrugprices.com
Medicaid 
claims
150 (306) 6 months4 biweekly
Minnesota (2004) www.state.mn.us/portal/mn/jsp/home.
do?agency=Rx
Medicaid 
claims
400 (700)
Since launch 
date 20045
biweekly
Missouri (2007)
www.morxcompare.mo.gov
Medicaid 
claims
1,300 (5,200) 6 months4 bimonthly
New Hampshire 
(2004)
www.egov.nh.gov/medicine-cabinet/
Drug_Listing.asp
Medicaid 
claims N/A
6 1 month Monthly
New Jersey (2007)
www.state.nj.us/lps/ca/njpdr/index.htm
Medicaid 
claims
150 (618) 1 year4 Weekly
New york (2004) www.nyagrx.org Price list 155 (158) N/A4,7 Monthly
Vermont (2007) www.atg.state.vt.us/display.
php?smod=185
Medicaid 
claims
90 (237) 1 month Monthly
1. The number of drugs may not be comparable across states because some states only count brand name drugs in their tallies while others count the number of brand name drugs and generic substitu-
tions separately.  
2. Where not provided by the state, the counts of formulations were tallied by HSC researchers.  In these cases, some rounding may have been performed. Formulations may include different dosages, 
quantities and suspensions of the same drug.  
3. Some states allow pharmacies to update their published u&C prices if they are outdated, so that updates may occur more frequently than what is reported on the state’s Web site.
4. For this state, at the time the price update occurs, if a pharmacy has not submitted a new Medicaid claim for a particular drug/formulation, the Web site will retain the existing price information; as a 
result, that price information could date as far back as the maximum length of the reporting period. 
5. Minnesota does not purge the price data after a specific duration of time has elapsed. Consequently prices may date back as far as the year the Web site was launched (2004) if a pharmacy has not sub-
mitted a more recent claim for a particular drug/formulation.   
6. No accurate count of drugs was available for New Hampshire because its total count encompasses all claims paid by Medicaid including the following items: medical supplies and devices, dietary 
supplements, and over-the-counter products. The total count of all searchable items in New Hampshire was 2,051 unique items (2,531 formulations).
7. A subset of all state pharmacies is visited monthly by volunteers who collect price sheets with retail prescription prices; the price sheets are used to update the information on NyAGrx.org. If a phar-
macy wasn’t surveyed in the prior month, then the price information from the most recent survey is reported. HSC contacted state agency staff; the staff did not provide information pertaining to the 
maximum duration of the reporting period. 
Source: HSC analysis of information available on state drug price comparison Web sites; supplemental information collected by telephone and e-mail exchanges between HSC researchers and state agency staff 
or private data contractors
This problem may result, at least in part, 
from the fact that these Web sites gener-
ally lack dedicated staff and funding, and 
that responsibility for these Web sites tend 
to be split between two agencies (often 
with the state Medicaid agency providing 
the price data and pharmacy information, 
and the Attorney General’s office develop-
ing and maintaining the Web site).
A reporting period of only one month 
poses problems for the comprehensive-
ness of the price data (i.e., the number 
of pharmacies reporting a price for each 
drug). In response to this problem, some 
states have opted to use longer report-
ing periods—for example, six months 
(Michigan, Missouri), one year (New 
Jersey), or even dating back to the incep-
tion of the Web site (Minnesota)—to 
reduce the amount of missing price data. 
In an effort to make the price data as 
current as possible, while still maintain-
ing comprehensiveness, most of these 
states have adopted frequent data update 
schedules—weekly updates in New Jersey 
and biweekly updates in Michigan and 
Minnesota. With each update, if new 
drug price data are available, the new 
data replace older data; if no new price 
data are available, then the existing data 
remain on the Web site until the data col-
lection period expires. 
This approach—an effort to balance 
competing objectives of data comprehen-
siveness and timeliness—provides a much 
fuller set of price data than would be pos-
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Table 2
Noteworthy Features of State Drug Price Comparison Web Sites
Search Features Examples of States with the Feature
Modify geographic area of drug search 
(user-specified radius distance from zip 
code or city)
Connecticut, Michigan, New york
Search for prices for multiple drugs 
simultaneously
Maryland, Michigan
Information Display Features Examples of States with the Feature
report data that price information was 
reported
New Jersey
Display pharmacy phone number Florida, Michigan, Missouri, New 
Hampshire, New york
Sort price table by different fields (e.g., 
price, zip code, pharmacy name)
Connecticut, Florida, Michigan, 
Missouri, New york, Vermont
Link to map of pharmacy location Florida, Michigan, Minnesota, Missouri, 
New york
"Vanguard" Options for Consumer 
Shopping
Examples of States with the Feature
Indicates if price match or senior dis-
count is available at a pharmacy
New york
Provides price list of generics offered at 
discount at selected pharmacies
Michigan
Links to Canadian Online Pharmacies Minnesota, New Hampshire
Miscellaneous Features Examples of States with the Feature
Spanish language version Florida, New Jersey
sible with a shorter reporting period. but the 
information can be misleading to consumers, 
because the prices listed for the same drug 
at competing pharmacies may have been 
obtained at different times over an extended 
reporting period, and older prices are less 
likely to still be in effect. Of the states using 
this approach, only New Jersey posts the date 
on which each price was reported. Michigan 
and Missouri provide general disclaimers that 
posted price information may be out of date 
and encourage consumers to call pharmacies 
directly to double-check prices. 
Noteworthy Features of State Web Sites. 
Some state sites have features that may be 
particularly useful to consumers (see Table 
2). These features enhance flexibility and 
usability on several different dimensions: 
search capabilities, information display and 
consumer shopping options. States seeking 
to launch new Web sites or improve existing 
ones may want to consider replicating some 
of these features.
In terms of search capabilities, two fea-
tures are noteworthy. The first pertains to 
selection of the geographic area. Three states 
allow consumers to specify a search area 
within a radius distance (e.g., 5 or 10 miles) 
from a central point of a zip code; one of 
these states also allows this search function 
from a central point of a city. This feature 
offers consumers greater flexibility since they 
can specify a travel distance they consider 
reasonable, which may not coincide with 
the boundaries of any one county, city or zip 
code. The second search feature that may 
be particularly useful to consumers pertains 
to drug selection. Two Web sites allow con-
sumers to specify multiple drugs on which 
to perform simultaneous price searches (6 
drugs in Maryland; 5 in Michigan). For 
consumers shopping for multiple drugs, this 
feature yields a very useful price table, which 
presents side-by-side comparisons of each 
of the requested drug prices offered by each 
pharmacy.
Once a drug price search has been con-
ducted and a price table has been generat-
ed, several information display features are 
helpful to consumers. The first two help 
the consumer to assess the accuracy of the 
price information. The first feature, not 
provided by most states, is a display of the 
date when each drug price was obtained, 
allowing consumers to assess how cur-
rent the price data is. The second feature, 
offered by several states, is a display of 
pharmacy contact information, making it 
easy for consumers to call pharmacies to 
verify prices. Other information display 
features that may be helpful to consumers 
include the ability to sort the price table 
by various fields (e.g., drug prices), and 
the inclusion of mapping tools to help 
consumers locate pharmacies. 
In addition, there are three useful 
features that go beyond the information 
provided by most Web sites in enhancing 
consumers’ drug shopping options. First, 
one state (New york) identifies which 
pharmacies will match prices offered 
by other local stores; this feature would 
enable consumers to obtain the lowest 
(local) prices with one-stop shopping. 
Second, another state (Michigan) pro-
vides a price table showing which generic 
drugs are available at steeply discounted 
prices at particular pharmacies (including 
Wal-Mart, Sam’s Club, Target, Kmart and 
Meijer, a local discount chain). This price 
list gives consumers a straightforward, 
easy-to-use tool for locating low prices 
for many generics. Finally, Minnesota 
and New Hampshire offer a feature that 
expands drug comparison shopping 
beyond the local geographic area. They 
provide links from their sites to Canadian 
online pharmacies and instructions for 
ordering from those pharmacies. For 
consumers needing brand-name medica-
tions, Canadian sites offer potentially large 
savings. 
Finally, Florida and New Jersey offer 
Spanish-language versions of their Web 
sites, which may be useful in expanding 
the programs’ reach.
A Closer Look at Florida’s 
Web Site, MyFloridaRx.com
Florida’s program was selected for in-
depth analysis because it is the most 
prominent and well known, and among 
the most long-standing, of the state 
pharmacy price transparency initiatives. 
Florida’s Web site, MyFloridaRx.com, 
was assessed on a variety of dimensions, 
including availability and accuracy of 
price information and overall usability. 
The analysis was conducted beginning 
in mid-2007, using the price data posted 
at that time on MyFloridaRx.com, which 
pertained to prices reported as being in 
effect in April 2007. The prices reported 
on MyFloridaRx.com are usual and cus-
tomary prices obtained from Medicaid 
claims forms. To conduct the analysis of 
MyFloridaRx.com, drug price searches 
were conducted using two  strategies—a 
Top 10 drug list and a set of consumer 
drug profiles— applied in different geo-
graphic markets: urban, suburban and 
rural.
Price Availability: Top 10 Drug List. 
The Top 10 drug list, obtained from a 
large pharmacy benefit manager, was used 
to assess the comprehensiveness of price 
information available from MyFloridaRx.
com. If the Web site was missing price data 
from a substantial proportion of pharma-
cies for these drugs, then the problem of 
missing data was likely to be at least as 
extensive for other, less commonly pre-
scribed drugs. The key finding from the 
Top 10 drug analysis was that the extent 
of missing price data was substantial and 
widespread across the urban, suburban 
and rural markets studied. 
The urban market examined in this 
analysis encompasses a radius of approxi-
mately 2.5 miles centered on the city of 
Hialeah, in Miami-Dade County. This 
market was selected for analysis because 
it contained an especially high number of 
retail pharmacies (70) in a relatively com-
pact geographic area, and thus appeared 
to provide conditions especially conducive 
to consumer shopping and pharmacy 
competition.
In the urban Hialeah market, none of 
the Top 10 drugs had price information 
available from all the local pharmacies 
(see Table 3). The three drugs with the 
most available price information still were 
lacking price data for 20 percent to 29 
percent of the 70 pharmacies in the city. 
The other seven drugs were missing price 
data from at least half the pharmacies in 
the market. Among these seven drugs, 
two were missing at least three-quarters 
of their price data, and one drug (hydro-
codone/acetaminophen) was excluded 
altogether from MyFloridaRx.com, 
because it is a pain medication considered 
subject to abuse. 
When the analysis of price availability 
for the Top 10 drugs was replicated in a 
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The key finding from the Top 10 drug analysis was that the extent of 
missing price data was substantial and widespread across the urban, 
suburban and rural markets studied. 
suburban market—Leon County in the 
Tallahassee area—the problems with miss-
ing data were exacerbated. In this suburban 
market, containing 29 pharmacies within 
an approximate radius of 5 miles, all 10 of 
the most common drugs had missing data 
for more than half of the pharmacies; all 
but one drug had missing data for two-
thirds or more of the pharmacies; and a 
few drugs had almost completely missing 
data (see Table 4). This problem apparently 
resulted from low numbers of Medicaid 
pharmacy transactions taking place in this 
suburban market, leading to very sparse 
price information.
In rural Putnam County—a market 
with 11 pharmacies within a radius of 
approximately 15 miles from the county’s 
center—missing price information for the 
Top 10 drugs was less of a problem than it 
was for suburban Leon County (see Table 
5), because pharmacies in rural Putnam 
County saw greater concentrations of 
Medicaid pharmacy transactions. Still, the 
proportion of Putnam County pharma-
cies with missing price information was 
substantial, ranging from 18 percent to 100 
percent across the Top 10 drugs. Compared 
to the urban Hialeah market, Putnam 
County had lower proportions of missing 
data for some Top 10 drugs. However, the 
much smaller number of pharmacies (11 
vs. 70) spread over a substantially larger 
travel distance (15-mile vs. 2.5-mile radius) 
likely makes missing price information a 
more serious impediment for would-be 
comparison shoppers in rural markets 
compared to urban settings.
Price Availability and Web Site 
Usability: Consumer Profiles. In a sepa-
rate assessment of price availability on 
MyFloridaRx.com, drug profiles were creat-
ed to represent five consumers with a range 
of medical conditions and prescription 
drug needs (see Table 6). Consumers 1 and 
2 need only one prescription each, while 
Consumers 3, 4 and 5 each need at least 
two drugs each for multiple health condi-
tions. Consumer 1 has a one-time medica-
tion need to treat an acute condition, while 
the other four consumers have ongoing 
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Table 3 
Availability of Drug Price Information and Range of Available Prices for Top 10 Drugs in Urban Market (Hialeah, 
Fla.)
Drug Name and Strength1 Pharmacies 
with Missing 
Price Data 
(out of 70 
Pharmacies)2
Minimum 
Price 
Available
Median 
Price 
Available
Maximum 
Price 
Available
Range of 
Available 
Prices: 
Minimum-
Maximum 
Price
Ratio of 
Available 
Prices: 
Maximum/
Minimum
Amoxicillin (500mg)3 43 $13.32 $23.35 $32.43 $19.11 2.4
Atenolol (50mg) 19 7.95 25.79 42.22 34.27 5.3
Hydrochlorothiazide (25mg) 14 2.38 7.99 11.99 9.61 5.0
Hydrocodone/
acetaminophen(500/5mg)4 70 N/A N/A N/A N/A N/A
Levothyroxine sodium 
(50mcg)5 55 10.99 13.26 17.20 6.21 1.6
Lipitor (10mg) 36 81.75 93.99 131.66 49.91 1.6
Lisinopril (10mg) 20 5.10 31.27 82.50 77.40 16.2
Synthroid (50mcg) 42 18.23 21.76 27.99 9.76 1.5
Toprol XL (25mg) 52 29.84 35.74 51.09 21.25 1.7
Zoloft (100mg) 42 59.90 100.00 187.64 127.74 3.1
Note: Price data were downloaded from MyFloridaRx.com in May 2007; according to MyFloridaRx.com these data were based upon usual and customary prices submitted with Medicaid pharmacy 
transactions during April 2007.
1. Drug prices pertain to a quantity of 30 pills unless otherwise indicated.
2. 70 pharmacies in Hialeah, Fla., submitted at least one Medicaid claim containing a usual and customary price during April 2007. The total number of retail pharmacies in the market may be greater 
than 70. 
3. My FloridaRx.com did not report a price for amoxicillin 500mg twice daily for ten days (total of 40 pills); to estimate the price of that prescription, the price for amoxicillin 500mg 30 pills was multi-
plied by 4/3.
4. Hydrocodone/acetaminophen is excluded from the MyFloridaRx.com because the drug is considered to have a potential for abuse.
5. Price information includes Levoxyl and Levothroid, which are alternatives to levothyroxine sodium.
Source: HSC analysis of MyFloridaRx.com Web site with supplemental information provided by state agency staff
drug needs to treat chronic conditions. 
The analysis of the consumer drug profiles 
used the same 2.5-mile-radius urban mar-
ket, Hialeah, employed in the Top 10 drug 
analysis.
Among the five consumers, Consumer 
2, taking Advair to treat asthma, would 
find MyFloridaRx.com the most useful in 
finding price information relevant to her 
drug needs (see Table 7). Price informa-
tion on Advair is far from complete, with 
fewer than half (32 of 70) of the pharmacies 
reporting Advair price data. However, the 
number of available pharmacies and the 
price range among those pharmacies are 
both large enough that Consumer 2 has the 
potential to reap substantial savings from 
using the Web site to compare prices for 
Advair.
Consumer 4, needing three prescrip-
tions to treat three chronic conditions, 
would find MyFloridaRx.com useful in 
comparing prices for two of his drugs and 
less useful for the third. both atenolol 
(for high blood pressure) and metformin 
(for diabetes) have price data available for 
approximately three-quarters of Hialeah 
pharmacies, and the price ranges for both 
drugs are large enough to suggest consider-
able savings from comparison shopping.7  
The other drug prescribed for Consumer 
4, Zetia (for high cholesterol), has much 
less price information—with only 10 of 70 
pharmacies in Hialeah reporting a price—
and a narrower price range among the 
available pharmacies, so the usefulness of 
the Web site in comparing Zetia prices is 
considerably more limited than for the two 
other drugs. To obtain the lowest available 
prices for Consumer 4’s three drugs, as 
reported by MyFloridaRx.com, Consumer 4 
would need to visit three different pharma-
cies, with a travel distance of eight miles 
among the pharmacies (not counting any 
travel time from the consumer’s home or 
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Table 4 
Availability of Drug Price Information and Range of Available Prices for Top 10 Drugs in Suburban Market (Leon 
County, Fla.)
Drug Name and Strength1 Pharmacies 
with Missing 
Price Data 
(out of 29 
Pharmacies)2
Minimum 
Price 
Available
Median 
Price 
Available
Maximum 
Price 
Available
Range of 
Available 
Prices: 
Minimum-
Maximum 
Price
Ratio of 
Available 
Prices: 
Maximum/
Minimum
Amoxicillin (500mg)3 22 $18.65 $26.65 $26.65 $8.00 1.4
Atenolol (50mg) 23 10.99 12.74 363.964 352.97 33.1
Hydrochlorothiazide (25mg) 15 4.00 10.97 11.99 7.99 3.0
Hydrocodone/
acetaminophen(500/5mg)5 29 N/A N/A N/A N/A N/A
Levothyroxine sodium 
(50mcg) 27 14.54 127.59 240.63
4 226.09 16.5
Lipitor (10mg) 24 86.59 92.99 100.70 14.11 1.2
Lisinopril (10mg) 20 4.00 20.49 415.80
4 411.80 104.0
Synthroid (50mcg) 26 20.94 21.29 25.99 5.05 1.2
Toprol XL (25mg) 28 40.97 40.97 40.97 0.00 1.0
Zoloft (100mg) 26 99.99 105.00 108.95 8.96 1.1
Note: Price data were downloaded from MyFloridaRx.com in July 2007; according to MyFloridaRx.com these data were based upon usual and customary prices submitted with Medicaid pharmacy trans-
actions during April 2007.
1. Drug prices pertain to a quantity of 30 pills unless otherwise indicated.
2. 36 pharmacies in Leon County submitted at least one Medicaid claim containing a usual and customary price during April 2007. The total number of retail pharmacies in the market may be greater 
than 36. Of the 36 pharmacies, 29 were within the catchment area, constructed as a 5 mile radius, centered on zip code 32808.  The catchment area included all or part of zip codes: 32301, 32303, 32304 
and 32312.
3. MyFloridaRx.com did not report a price for amoxicillin 500mg twice daily for ten days (total of 40 pills); to estimate the price of that prescription, the price for amoxicillin 500mg 30 pills was multi-
plied by 4/3.
4. Telephone checks by HSC researchers to the pharmacy reporting the maximum price yielded price quotes that were at or below the median price ($11 to $14) for each prescription; the prices posted 
on MyFloridaRx.com for those drugs at that pharmacy appear to be due to data reporting or calculation errors.
5. Hydrocodone/acetaminophen is excluded from the MyFloridaRx.com because the drug is considered to have a potential for abuse.
Source: HSC analysis of MyFloridaRx.com Web site with supplemental information provided by state agency staff
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workplace to reach the pharmacies). 
Consumer 5, who also needs three pre-
scriptions to treat three different chronic 
conditions, would find the Florida Web 
site useful in comparing prices for only 
one of his three prescribed medications—
sertraline (for depression), which has 
price information from 42 of Hialeah’s 70 
pharmacies and a considerable price spread 
among pharmacies.8 The other two drugs 
needed by this consumer, omeprazole (for 
gastroesophageal reflux) and clonazepam 
(for anxiety disorder) are not available at all 
on MyFloridaRx.com. Overall, Consumer 5 
would find the Web site’s usefulness quite 
limited. 
The two remaining consumers would 
not find MyFloridaRx.com helpful in com-
paring prices for the medications they 
need. Even though Consumer 1 has only 
a single prescription need—the brand-
name antibiotic Levaquin (for an acute 
infection)—the drug would not appear 
in a search within Hialeah because no 
Medicaid claims for this drug were submit-
ted by Hialeah pharmacies for April 2007. 
MyFloridaRx.com advises users to expand 
the geographic search area if the drug is not 
available for the initial search area. In this 
instance, Consumer 1 could have widened 
the search area to Miami-Dade County 
and would have found the nearest phar-
macy quoting a price to be 8 miles from 
central Hialeah and the nearest pharmacy 
quoting the lowest (county-wide) price 
to be 10 miles away. It is unclear whether 
a consumer with a one-time need for a 
seven-day prescription would be motivated 
to comparison shop, particularly if obtain-
ing a lower price requires significant travel 
distance.
The other consumer whose needs 
would not be met by MyFloridaRx.com is 
Consumer 3, who is prescribed Fosamax 
(for osteoporosis) and hydrocodone/acet-
aminophen (for chronic back pain). Of the 
70 pharmacies in Hialeah, only one had a 
price listed for Fosamax, while none had 
Table 5
Availability of Drug Price Information and Range of Available Prices for Top 10 Drugs in Rural Market (Putnam 
County, Fla.)
Drug Name and Strength1 Pharmacies 
with Missing 
Price Data 
(out of 11 
Pharmacies)2
Minimum 
Price 
Available
Median 
Price 
Available
Maximum 
Price 
Available
Range of 
Available 
Prices: 
Maximum-
Minimum Price
Ratio of 
Available 
Prices: 
Maximum/
Minimum
Amoxicillin (500mg)3 2 $5.33 $18.65 $26.65 $21.32 5.0
Atenolol (50mg) 8 4.00 7.15 7.75 3.75 1.9
Hydrochlorothiazide (25mg) 2 4.00 7.38 11.99 7.99 3.0
Hydrocodone/
acetaminophen(500/5mg)4 11 N/A N/A N/A N/A N/A
Levothyroxine sodium 
(50mcg) 7 6.50 11.78 15.09 8.59 2.3
Lipitor (10mg) 6 86.59 88.42 93.75 7.16 1.1
Lisinopril (10mg) 3 4.00 16.40 20.49 16.49 5.1
Synthroid (50mcg) 7 19.84 22.12 22.95 3.11 1.2
Toprol XL (25mg)5 3 15.05 17.39 22.78 7.73 1.5
Zoloft (100mg) 8 86.25 95.05 99.99 13.74 1.2
Note: Price data were downloaded from MyFloridaRx.com in July 2007; according to MyFloridaRx.com these data were based upon usual and customary prices submitted with Medicaid pharmacy trans-
actions during April 2007.
1. Drug prices pertain to a quantity of 30 pills unless otherwise indicated.
2. 11 pharmacies in Putnam County submitted at least one Medicaid claim containing a usual and customary price during April 2007. The total number of retail pharmacies in the market may be greater 
than 11.
3. MyFloridarx.com did not report a price for amoxicillin 500mg twice daily for ten days (total of 40 pills); to estimate the price of that prescription, the price for amoxicillin 500mg 30 pills was multi-
plied by 4/3.
4. Hydrocodone/acetaminophen is excluded from the MyFloridaRx.com because the drug is considered to have a potential for abuse.
5. MyFloridarx.com did not publish a price for Toprol XL at a 25mg dosage; to estimate the price of that prescription, the published price for Toprol XL 50mg was divided by two; this assumes a con-
sumer will split the 100mg dosage into two dosages of 50mg each.
Source: HSC analysis of MyFloridaRx.com Web site with supplemental information provided by state agency staff
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a price for hydrocodone/acetaminophen, 
which was excluded from the Web site 
because of concerns about potential abuse. 
If Consumer 3 had widened her search for 
Fosamax to all of Miami-Dade County, 
she could have traveled approximately 8 
miles from central Hialeah to the nearest 
pharmacy in Miami and saved nearly $100 
on her prescription. The sparse data for 
Fosamax on MyFloridaRx.com points to 
one of the weaknesses of using Medicaid 
transactions as a data source: Certain pop-
ulation subgroups, such as women in their 
50s, are underrepresented in the Medicaid 
population; consequently, the drugs they 
commonly take also will be underrepre-
sented.
Of the five consumers profiled, only 
one consumer would find her informa-
tion needs substantially met by using 
MyFloridaRx.com. The four other consum-
ers have at least one medication for which 
the Web site provides little or no price 
information. This finding is consistent with 
results of the Top 10 drug analysis, which 
found that missing price information is a 
serious issue that substantially limits the 
Web site’s usefulness.
Price Accuracy: Top 10 Drug List. 
Telephone calls were made to a subset of 
pharmacies to spot check how well the 
prices listed on MyFloridaRx.com for the 
Top 10 drugs matched the prices quoted 
by pharmacies to callers identifying them-
selves as cash-paying customers. The results 
of this analysis showed that MyFloridaRx.
com prices were generally quite accurate 
for chain drugstores and for pharmacies 
in supermarkets and mass-market retail-
ers. For independent pharmacies, however, 
the prices quoted by phone differed from 
the MyFloridaRx.com prices for all the 
cases checked. Where prices differed, the 
telephone quote usually was almost always 
lower than the published price. While this 
analysis was only a random spot check and 
was not meant to be definitive, there is a 
pattern suggesting that drug prices posted 
for independent pharmacies are substan-
tially less reliable than those for major 
retailers. This discrepancy may result from 
drug prices fluctuating more frequently, 
and perhaps price reporting errors occur-
ring more often, at independent pharma-
cies as compared to larger retailers. 
In addition to these random price 
checks, selected outlier prices were checked 
in the suburban Leon County market. For 
three of the Top 10 drugs, prices listed 
on MyFloridaRx.com for one pharmacy 
were so high (10 to 30 times the median 
price) that they appeared to be data errors. 
Indeed, telephone calls to that pharmacy 
confirmed that the usual and customary 
prices offered by the pharmacy were much 
lower than those reported on MyFloridaRx.
com and were, in fact, lower than the medi-
an prices for those drugs. In a follow-up 
interview, state Medicaid agency staff con-
firmed that the Web site does not currently 
have a system for identifying data outliers 
and verifying the underlying price data. As 
a result, it is not clear whether the wrong 
prices posted on the Web site resulted from 
reporting errors by the pharmacy or data 
calculation errors by the state Medicaid 
agency. 
Price Variation: Top 10 Drug List. The 
substantial degree of missing price data on 
MyFloridaRx.com, along with the existence 
of price data outliers, means that it is not 
possible to use the Web site to assess the 
extent of drug price variations in a defini-
tive manner. Instead, an attempt was made 
to examine different dimensions of price 
variation to the extent possible given the 
incomplete price data. 
First, the available price data for the Top 
10 drugs were examined to assess whether 
there were any discernible patterns in 
median prices and price ranges across mar-
kets. Some drugs (e.g., Synthroid) had rela-
tively modest price dispersion, while others 
(e.g., lisinopril) showed a much broader 
price range across pharmacies. One pat-
tern observed was that rural Putnam 
County tended to have lower median prices 
and smaller price ranges than the urban 
Hialeah and suburban Leon County mar-
kets. This observation, however, may not 
apply to drug prices beyond the Top 10 
list, and may not be generalized to markets 
beyond these three specific areas.
Second, an examination was made of 
whether pharmacies tended to be consis-
tently low-priced or high-priced relative 
to local competitors or whether their price 
rankings fluctuated across drugs. Again, it 
was not possible to conduct this analysis 
in a definitive way, given the missing data. 
Instead, a subset of Hialeah pharmacies 
that had relatively complete price data for 
the Top 10 drugs was created (defined as 
having prices for at least seven drugs). The 
pharmacies were then ranked by quartile 
based on their prices for each drug rela-
tive to the prices of other pharmacies. This 
analysis found that pharmacies were not 
consistently high- or low-priced relative 
Of the five consumers profiled, 
only one consumer would find 
her information needs substan-
tially met by using MyFloridaRx.
com. the four other consumers 
have at least one medication for 
which the Web site provides little 
or no price information. 
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Table 6 
Consumer Profiles
Consumer 1 A 23-year-old previously healthy woman who takes no routine medica-
tions is prescribed 
Levaquin (levofloxacin) 500mg orally daily for 7 days for an acute 
kidney infection
Consumer 2 A 47-year-old woman is prescribed
Advair (salmeterol/fluticasone) 50/500mcg 2 puffs twice daily for 
asthma
Consumer 3 A 54-year old woman is prescribed
Fosamax (alendronate) 70 mg/75ml orally weekly for osteoporosis 
hydrocodone/acetaminophen (generic) 500/5mg two tablets twice 
daily for chronic back pain
Consumer 4 A 62-year old man is prescribed
atenolol (generic) 100mg orally daily for high blood pressure
Zetia (ezetimibe) 10mg orally daily for high cholesterol, with a his-
tory of adverse reaction to statin medications
metformin (generic) 500mg orally twice daily for type 2 diabetes
Consumer 5 A 58-year old man is prescribed
sertraline (generic) 50mg orally daily for depression
omeprazole (generic) 20mg orally daily for gastroesophageal reflux
clonazepam (generic) 1mg orally twice daily for anxiety disorder
Source: Actual patients in a physician practice. See Data Source for more information.
to others in the market. Instead, pharma-
cies that were in the lowest price bracket 
for some drugs tended to be in the highest 
price bracket for others. This finding is 
consistent with previous research, which 
found that retail pharmacies in upstate 
New york markets tended not be con-
sistently high- or low-priced relative to 
local competitors.9 A key implication of 
this finding is that savings for consumers 
inclined to fill multiple prescriptions at a 
single pharmacy will be limited.
The analysis described in this study  is 
only a snapshot of one moment in time; 
it does not examine what may have hap-
pened to average price levels, and extent of 
price dispersion, over time. Managers of 
MyFloridaRx.com at Florida’s Agency for 
Health Care Administration did conduct 
an analysis comparing price spreads for 
certain drugs at two moments in time: 
at the time of the Web site’s launch and 
approximately six months later. The state’s 
analysis focused on drugs that showed a 
broad price range in the pre-launch period 
and found that this price range had nar-
rowed substantially in the post-launch 
period. MyFloridaRx.com managers con-
cluded that the “sunshine” effect of seeing 
their prices made public on the Web site 
caused high-priced pharmacies to lower 
their prices considerably, thus yielding 
significant benefits to consumers. It is 
important to note some important cave-
ats to that conclusion, however: (1) The 
posted prices on MyFloridaRx.com do not 
represent actual transaction prices paid by 
consumers, so it is not possible to quantify 
any savings that consumers may have real-
ized; (2) As noted earlier, MyFloridaRx.
com does not have a system for identify-
ing and removing data outliers—the high 
prices reported in the pre-launch period 
may have been data errors that later were 
corrected in subsequent reporting periods; 
and (3) The analysis did not examine what 
happened to price ranges for those drugs 
in other markets (without price compari-
son Web sites) outside of Florida, leaving 
open the possibility that external factors—
rather than the price transparency initia-
tive itself—may have been responsible for 
reductions in price dispersion across all 
markets. 
Usability Features of MyFloridaRx.
com. Compared to some other states’ Web 
sites, MyFloridaRx.com’s search capabilities 
are not as flexible and powerful: It does 
not allow consumers to specify a radius-
distance search area or conduct simultane-
ous price searches for multiple drugs. The 
site also does not contain information on 
local pharmacy price matching and gener-
ic discount lists. Finally, MyFloridaRx.
com does not report the date each price 
was obtained; however, pharmacy contact 
information is provided for consumers to 
call to verify prices. 
Compared to other states, 
MyFloridaRx.com offers relatively more 
information display features that improve 
this analysis found that pharma-
cies were not consistently high- or 
low-priced relative to others in the 
market. Instead, pharmacies that 
were in the lowest price bracket 
for some drugs tended to be in the 
highest price bracket for others. 
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Table 7 
Availability and Usefulness of Price Information for Consumers Conducting Drug Searches in Urban Hialeah, Fla., 
on MyFloridaRx.com
Medical 
Condition
Prescription1 Drug Available?2 Pharmacies 
with Price 
Data 
(Out of 70 
Pharmacies)3
Range of 
Available 
Prices: 
Minimum-
Maximum 
Price
Assessment 
of Price 
Information
MyFloridaRx.
com
Hialeah 
Market
Consumer 
1
Kidney Infection Levaquin (levofloxacin) 
(500mg orally daily for 7 
days)
yes No 0 N/A
Not useful
Consumer 
2
Asthma Advair (salmeterol/flutica-
sone) (50/500mcg 2 puffs 
twice daily)
yes yes 32 $150 ($248-
398) useful
Consumer 
3 Osteoporosis
Fosamax (alendronate) 
(70mg/75ml orally once per 
week)
yes yes 1 $204 Not useful
Chronic back 
Pain
Hydrocodone/acetamino-
phen (generic)4 (500/5mg 2 
tablets orally twice daily)
No No N/A N/A Not useful
Consumer 
4
High blood 
Pressure
Atenolol (generic) (100mg 
orally daily5
yes yes 51
$68 
($16-$84)
useful
High Cholesterol
Zetia (ezetimibe) (10mg 
orally daily)
yes yes 10
$29 
($92-$121)
Somewhat 
useful
Type 2 Diabetes
Metformin (generic) 
(500mg orally twice daily)6
yes yes 54 $70 ($7-77) useful
Consumer 
5 Depression
Sertraline (generic)7 (50mg 
orally daily)
yes yes 42 $59 ($3-62) useful
Gastroesophageal 
reflux
Omeprazole (generic) 
(20mg orally daily)
No No N/A N/A Not useful
Anxiety Disorder
Clonazepam (generic) (1 
mg orally twice daily)
No No N/A N/A Not useful
Note: Price data were downloaded from MyFloridaRx.com in June 2007; according to MyFloridaRx.com these data were based upon prices submitted with Medicaid pharmacy transactions during April 
2007.
1. Drug prices pertain to a quantity of 30 pills unless otherwise indicated. 
2. Drug availability column denotes whether the prescription was (a) available on MyFloridaRx.com and (b) available in the Hialeah market (within a county search of Miami-Dade).
3. 70 pharmacies in Hialeah submitted at least one Medicaid claim containing a usual and customary price during April 2007. The total number of retail pharmacies in the market may be greater than 
70.
4. Hydrocodone/acetaminophen is excluded from the MyFloridaRx.com because the drug is considered to have a potential for abuse.
5. MyFloridaRx.com did not publish a price for atenolol at a 100mg dosage; to estimate the price of that prescription, the published price for atenolol 50mg was multiplied by two; this assumes Consumer 
4 will take two 50mg pills daily.
6. The MyFloridaRx.com price for metformin reflects a quantity of 60 pills, therefore no adjustments to the dosage and price were made.
7. MyFloridaRx.com did not publish a price for sertraline at a 50mg dosage; to estimate the price of that prescription, the published price for sertraline 100mg was divided by two; this assumes Consumer 
5 will split the 100 mg dosage into two dosages of 50mg each.
Source: HSC analysis of MyFloridaRx.com Web site with supplemental information provided by state agency staff.
the usability of the Web site, including the 
ability to sort price tables, export price 
tables as spreadsheets, and link to maps of 
pharmacy locations. Finally, MyFloridaRx.
com is also one of the only state Web sites 
available in a Spanish-language version.
Policy Implications
The gaps in available price data at 
MyFloridaRx.com suggest that a drug price 
comparison initiative relying on Medicaid 
claims data inevitably will be subject to 
incomplete price information. As noted 
above, some states using Medicaid data 
for their drug price comparison Web sites 
have attempted to reduce data omissions 
by expanding the data-reporting period, 
but this approach lessens the timeliness 
and, consequently, the accuracy of the price 
data. When consumers compare prices 
using Web sites whose data reporting 
periods are extended over a long period, 
they may be making an apples to oranges 
comparison, comparing a recent price at 
one pharmacy with a much older price at 
another.
An alternative approach to providing 
price data for drug comparison Web sites—
one that has been considered by policy 
makers in several states but adopted by 
none to date—is to require pharmacies to 
submit prescription drug price lists on a 
regular, frequent basis (e.g., every month) 
to a state agency, which would post these 
on the drug price comparison Web site. A 
chief architect of the MyFloridaRx.com pro-
gram remarked that it had been an over-
sight to omit mandated price-list reporting 
from the 2004 legislation that authorized 
the Web site, and that, in retrospect, that 
approach would have provided substan-
tially more complete and useful price 
information for consumers than the use of 
Medicaid claims data. Whenever mandated 
price-list reporting has been proposed, 
it has faced strong resistance from retail 
pharmacy associations, which claim that 
the reporting burden would be heavy. Some 
experts, however, suggest that this burden 
is overstated, given that almost all prescrip-
tion drug claims already are submitted elec-
tronically, so the same infrastructure could 
be used to transmit price lists electronically. 
It may be that many retailers prefer not 
have price transparency tools provided to 
consumers and are simply using reporting 
burden as the publicly acceptable argument 
to avert the introduction of those tools. 
With the advent of online pharma-
cies in recent years, consumer shopping 
for prescription drugs need no longer be 
restricted to pharmacies located within a 
certain distance from a consumer’s home 
or workplace. Consumer Reports notes that 
u.S.-based online pharmacies “generally 
sell drugs for less, sometimes substantially 
less (35% or more)” than brick-and-mortar 
retail pharmacies.10  To date, no state gov-
ernment has provided consumers with 
price comparisons from these online phar-
macies, but commercial initiatives such as 
DestinationRx.com and Pillbot.com have 
done so. For price queries on common 
drugs, these sites report a wide range of 
price quotes from online pharmacies—
from as few as one to as many as six quotes. 
States seeking to provide consumers with 
online pharmacy price comparisons may 
find it easy to provide links to these com-
mercial sites from state-hosted Web sites. 
A brief review of these commercial price 
comparison sites, however, found that the 
price quotes they provide sometimes did 
not match the prices obtained directly from 
the online pharmacies’ Web sites. As a 
result, states may prefer not to rely on these 
commercial sites, but instead to vet online 
pharmacies themselves and to provide price 
comparisons from these online pharmacies 
directly to consumers as part of the state’s 
price transparency initiative. Even consum-
ers who choose to purchase their prescrip-
tions locally may benefit from using such a 
Web site, as they will have benchmark pric-
es against which to compare local prices. 
u.S.-based online pharmacies are not 
the only Web sites from which consumers 
can purchase prescription medications. 
Policy debates and media coverage in 
recent years have highlighted the fact that 
brand-name drugs are often available at 
substantial savings from pharmacies based 
in Canada, the united Kingdom and other 
countries, compared to any type of phar-
macy in the u.S. buying prescription drugs 
from any foreign country except Canada 
is technically illegal, and the Canadian 
exemption applies only to drug purchases 
made in person, not to drug purchases 
from Canadian Web sites. However, u.S. 
Customs and border Protection agents cur-
rently are not enforcing this law; the agency 
is not seizing packages from Canadian 
pharmacies if they contain a 90-day supply 
or less and are for individual use.11  
Despite the fact that Congress has not 
legalized foreign drug purchases, some 
states already have undertaken initiatives to 
facilitate such purchases by state employ-
ees and other state residents. Minnesota, 
Wisconsin and New Hampshire are among 
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an alternative approach to pro-
viding price data for drug com-
parison Web sites—one that has 
been considered by policy mak-
ers in several states but adopted 
by none to date—is to require 
pharmacies to submit prescription 
drug price lists on a regular, fre-
quent basis.
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Center for Studying Health System Change Research Brief No. 1 • February 2008
the states that have inspected and certified 
Canadian Web sites that they consider reli-
able for online prescription transactions; 
these states have then provided links to 
these Canadian pharmacies, along with 
step-by-step ordering instructions, avail-
able to consumers via state Web sites.12  
Other states have shown interest in follow-
ing suit. The California law establishing 
the California rx Prescription Drug Price 
Web Site Program (Assembly bill 2877, 
September 2006) does not specifically 
mandate—but leaves open the possibility—
that the new Web site will contain informa-
tion for consumers about ordering from 
international pharmacies, once those phar-
macies have passed review by the state’s 
Department of Health Services.13 
One market development that has dove-
tailed with states’ efforts to increase price 
transparency has been the well-publicized 
initiative by discount retailers, led by Wal-
Mart, to provide some generic drugs at low 
prices (generally $4 for a 30-day supply). 
Wal-Mart launched the program in Tampa, 
Fla., in September 2006, and had expanded 
the program to 49 states by December 
2006. Its list of low-priced generics, which 
initially included approximately 140 drugs 
(totaling more than 300 formulations), was 
matched completely by Target and partially 
by Kmart (which offers 90-day supplies at 
$15 each). The lists are downloadable from 
these retailers’ Web sites and available at 
any of their pharmacy locations. 
Some experts questioned the overall 
usefulness to consumers of the $4 generics 
programs, asserting that many drugs on 
the list were older generics that were not 
commonly prescribed or highly priced in 
the first place. Other experts disagreed, cit-
ing as examples antibiotic, arthritis, asthma 
and cholesterol medications on the Wal-
Mart/Target list that were among the most 
frequently prescribed medications in their 
respective drug classes. In September 2007, 
Wal-Mart added 14 new drugs (totaling 
nearly 30 formulations) to its $4 generic 
list—additions that have been matched by 
Target. The new list includes some popular 
drugs that have recently come off patent, 
including terbinafine (the generic form 
of Lamisil, an antifungal medication) and 
carvedilol (the generic form of Coreg, a 
beta blocker used to treat congestive heart 
failure). An analysis found that the updated 
Wal-Mart/Target list of $4 generics includes 
approximately 70 percent of the most com-
monly prescribed generic drugs in the u.S. 
today,14 so claims that the list is composed 
mainly of older, less-used drugs do not 
appear to be supported.
Wal-Mart officials have indicated that 
they view state drug price comparison Web 
sites as an opportunity for them to broaden 
consumer awareness of their $4 generics 
program. Currently, however, most state 
Web sites do not make it easy for consum-
ers to identify which pharmacies offer 
which drugs at which discounted prices; 
consumers must search on a drug-by-drug 
basis, and the low prices would appear only 
if a Wal-Mart or Target within the search 
area had sold that drug to a Medicaid 
patient during the reporting period. 
Michigan, as noted earlier, is the excep-
tion: by presenting a table that clearly lists 
the exact discounted price offered by each 
discount retailer for each generic drug, the 
state’s Web site provides a useful resource 
to consumers.
States seeking to help consumers find 
the best retail prices for their prescription 
medications may need to take a multi-
pronged approach to optimize shopping 
resources for consumers. because drug 
price comparison Web sites drawing on 
Medicaid data inevitably contain large 
data gaps, states that seek to compare retail 
prices at local pharmacies may need to con-
sider mandating that each retail pharmacy 
submit price lists to the state. And, because 
shopping for medications may be most 
effective if it is not restricted to local mar-
kets, states may want to consider providing 
the following tools, most of which have 
been made available by at least one state:
A table showing which retailers offer •	
which generic drugs at steeply discounted 
prices.
A list identifying local pharmacies that •	
offer price matching.
A user’s guide and price comparison tool •	
for u.S.-based online pharmacies (such 
as that currently provided by commercial 
sites such as DestinationRx.com).
A user’s guide and price comparison •	
tool for Canada-based or other foreign-
based online pharmacies, which would 
be particularly helpful to consumers who 
need brand-name, as opposed to generic, 
drugs.
Employing all these approaches together 
would maximize shopping tools for con-
sumers, but it also would require consid-
erable state resources, particularly if the 
information is to be kept accurate and up 
States seeking to help consumers find the best retail prices for their pre-
scription medications may need to take a multi-pronged approach to 
optimize shopping resources for consumers. 
to date. States will need to weigh these costs 
realistically against the potential savings to 
consumers. As part of this process, policy 
makers should consider the types of con-
sumers most likely to seek out and benefit 
from these information sources; previous 
research suggests that it is consumers with 
high levels of education and Internet pro-
ficiency who will reap the most benefits.15  
These consumers, however, are among 
those least likely to lack health insurance in 
the first place. 
States also will need to consider whether 
it makes sense to duplicate other states’ 
efforts, in cases where the tools being 
provided are broader in scope than local 
or statewide (for example, when multiple 
states are providing comparison tools of 
online pharmacies). There is nothing to 
prevent well-informed consumers liv-
ing anywhere in the u.S. from using, for 
example, Minnesota’s Web site to help 
them order brand-name drugs from a set 
of Canadian pharmacies that have already 
been vetted by the state of Minnesota. 
Therefore, states launching initiatives to 
offer essentially the same information may 
be expending resources while adding little 
if any marginal benefit. 
Some experts have expressed the view 
that policy interventions aimed at helping 
consumers save on their prescription drugs 
should not be restricted to those that focus 
on promoting consumer shopping at the 
retail level. These experts assert that, com-
pared to drug manufacturers, retail phar-
macies have relatively little market power 
to affect the overall prices of prescription 
drugs, especially for single-source medica-
tions. In recognition of this, a few states—
California among them—have enacted 
laws establishing state prescription drug 
discount programs that seek to leverage 
the state’s Medicaid purchasing power to 
obtain discounts from drug manufacturers 
for state residents who lack drug coverage 
and fall below certain income thresholds 
(typically, 3 to 3.5 times the federal poverty 
level).16 Although each state’s discount pro-
gram differs somewhat, each program uses 
a two-step approach: first, the state negoti-
ates with drug manufacturers to obtain 
discounts (through rebates) for program 
participants; second, if manufacturers do 
not agree to sufficient rebates, the state has 
the authority to remove that manufacturer’s 
drugs from the state Medicaid program’s 
preferred drug list. removal from this list 
would subject those drugs to prior-autho-
rization requirements, which in turn would 
reduce sales of those drugs to the Medicaid 
program. 
Among the states with these drug dis-
count initiatives, Maine’s program, Maine 
rx Plus, has been regarded as the proto-
type. research suggests that Maine’s negoti-
ated discounts with drug manufacturers 
have resulted in substantial price reductions 
on some commonly prescribed drugs,17 but 
negotiations with other manufacturers have 
stalled. Most of these drug discount pro-
grams are still too new for their impact to 
be assessed, but the interest shown by many 
states in following Maine’s course suggests 
that many policy makers see a need to use 
tools beyond retail-level price transparency 
and consumer shopping in their efforts to 
help consumers obtain meaningful price 
reductions for prescription drugs.
15
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States also will need to consider whether it makes sense to duplicate 
other states’ efforts, in cases where the tools being provided are 
broader in scope than local or statewide.
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Notes
1. This is an issue relevant primarily to uninsured consumers, as insured consumers generally would have 
their full medication lists tracked and checked for potential interactions by their insurers’ pharmacy benefit 
managers (PbMs).
2. Consumer Reports, “Shopper’s Guide to Prescription Drugs, No. 3: Getting the best Price,” http://crbestbuy-
drugs.com/PDFs/BestPrice-FINAL.pdf, accessed on Nov. 28, 2007.
3. An exception would be steeply discounted generics offered by some large retailers, the full price of which 
might be less than an insured consumer’s copayment or coinsurance.
4. Missouri has prices for approximately 1,300 drugs (totaling approximately 5,200 formulations). No accurate 
prescription drug count was available for New Hampshire because its total count encompasses all claims 
paid by Medicaid, including medical supplies and devices, dietary supplements, and over-the-counter prod-
ucts.
5. Florida’s list of 100 distinct drugs refers to brand-name drugs only; the count of searchable brand-name 
drug and generic substitutes is approximately 150.
6. Ohio’s Web site, no longer active, relied on voluntary reporting by retail pharmacies of usual and customary 
prices for 25 prescription drugs to the Attorney General’s office. 
7. MyFloridaRx.com did not publish a price for atenolol at a 100 mg dosage; to estimate the price of that 
prescription, the published price for atenolol 50 mg was multiplied by two; this assumes Consumer 4 will 
take two 50 mg pills daily. This estimated drug price may differ from the true price of atenolol 100 mg.  
However, this approach simulates the process that a consumer, with access only to the information pro-
vided by MyFloridaRx.com, would undertake to estimate the drug cost. 
8. MyFloridaRx.com did not publish a price for sertraline at a 50 mg dosage; to estimate the price of that 
prescription, the published price for sertraline 100 mg was divided by two; this assumes Consumer 5 will 
split the 100 mg dosage into two dosages of 50 mg each. This estimated drug price may differ from the true 
price of sertraline 50 mg. However, this approach simulates the process that a consumer, with access only to 
the information provided by MyFloridaRx.com, would undertake to estimate the drug cost.
9. Sorensen, Alan T., “Equilibrium Price Dispersion in retail Markets for Prescription Drugs,” Journal of 
Political Economy, Vol 108, No. 4 (August 2000).
10. Consumer Reports.
11. Consumer Reports.
12. In Minnesota and New Hampshire, Canadian pharmacy information is provided at the same Web sites that 
provide local pharmacy price information. In Wisconsin, which does not provide the latter, Canadian phar-
macy information is provided at drugsavings.wi.gov.
13. With regard to international pharmacies, Ab 2877 stipulates only that the Department of Health Services is 
authorized “to assess a fee on international pharmacies that the department reviews for possible inclusion 
on the Web site to offset the cost of reviewing those pharmacies.”
14. Analysis was conducted using: (1) top 150 drug list obtain by the state of New Jersey from Pharmacy Times; 
(2) Wal-Mart price list, downloaded from http://i.walmart.com/i/if/hmp/fusion/four_dollar_drug_list.pdf. 
15. baker, Laurence C., et al., “use of the Internet and E-Mail for Health Care Information: results From a 
National Survey,” Journal of the American Medical Association, Vol. 289, No. 18 (May 14, 2003); Tu, Ha T., 
and J. Lee Hargraves, Seeking Health Care Information: Consumers Still on the Sidelines, Issue brief No. 61, 
Center for Studying Health System Change, Washington, D.C. (March 2003).  
16. The California law is Assembly bill 2911, signed into law in September 2006.  Other states with similar 
programs are Maine, New Hampshire and Hawaii. residents are eligible to participate at higher income 
thresholds if their family medical expenses are high (e.g., greater than 10% of family income).
17. Treat, Sharon Anglin, and Steven Samo, Cutting Drug Costs: Different Approaches, Different Results, 
Prescription Policy Choices, http://www.policychoices.org/reports/CutDrugCostsReportFINAL.pdf, accessed on 
Nov. 28, 2007.
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